EGFR-targeting polydopamine nanoparticles co-loaded with 5-fluorouracil, irinotecan, and leucovorin to potentially enhance metastatic colorectal cancer therapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: EGFR-targeting polydopamine nanoparticles co-loaded with 5-fluorouracil, irinotecan, and leucovorin to potentially enhance metastatic colorectal cancer therapy ; volume:14 ; number:1 ; day:26 ; month:11 ; year:2024 ; pages:1-14 ; date:12.2024
Scientific reports ; 14, Heft 1 (26.11.2024), 1-14, 12.2024

Creator: Djermane, Rania
Nieto, Celia
Vega, Milena A.
Valle, Eva M. Martín del

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-024-80879-0

URN: urn:nbn:de:101:1-2502112103129.875407959260

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:39 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Djermane, Rania
Nieto, Celia
Vega, Milena A.
Valle, Eva M. Martín del
SpringerLink (Online service)

Other Objects (12)

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers

Diazo transfer at polydopamine

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report

Hochschulschrift

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Hochschulschrift

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers

Diazo transfer at polydopamine

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report

Hochschulschrift

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Hochschulschrift

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers

Diazo transfer at polydopamine

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report

Hochschulschrift

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Hochschulschrift

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

EGFR-targeting polydopamine nanoparticles co-loaded with 5-fluorouracil, irinotecan, and leucovorin to potentially enhance metastatic colorectal cancer therapy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer

High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers

Diazo transfer at polydopamine

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer

High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers

Diazo transfer at polydopamine

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer

High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers

Diazo transfer at polydopamine

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Phase-III-Studie zur Erstlinienbehandlung des metastasierten kolorektalen Karzinoms : Irinotecan plus Oxaliplatin (mIROX) versus Irinotecan plus hochdosierte wöchentliche 24-Stunden-Infusion von 5-Fluorouracil plus Folinsäure (FUFIRI) ; the FIRE-trial

Related objects

Reset password